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Background: Identifying chronic obstructive pulmonary disease (COPD) patients at increased
risk of mortality is an important component of effective disease management.
Methods: A pooled analysis of patients with severe COPD, from two well-controlled 1-year stud-
ies, was conducted using Cox regression and spline analysis to evaluate predictability of baseline
demographic data and in-study variables for mortality risk, and to evaluate the effect of treat-
ment allocation to budesonide and formoterol, versus their respective control groups, on these
outcomes.
Results: In the pooled analysis, a Cox regression model reported a higher baseline St George’s
Respiratory Questionnaire (SGRQ) total score as a significant predictor of mortality (hazard ratio
1.037 [95% confidence interval 1.021e1.054]; p < 0.0001). The 36-item short-form health survey
(SF-36) mental and physical component scores were also predictive of an increased mortality
risk (p < 0.05). Age, forced expiratory volume in 1 s (FEV1), body mass index and smoking status
were not significant predictors. Spline analysis of baseline variables revealed a linear association
between SGRQ total score and mortality risk over 1 year (logarithmic scale). Other baseline vari-
ables, including FEV1, showed different bimodal patterns in the spline analysis. There was no
difference in mortality in the formoterol versus the non-formoterol treatment group while bu-
desonide-containing treatment was associated with reduced 1-year, all-cause, in-study mortal-
ity compared with non-budesonide therapy.r is available as both trials included in this pooled analysis began enrolment before 1 July 2005.
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1616 D.M.G. Halpin et al.Conclusion: Health status measured by SGRQ and SF-36 may be important for predicting COPD
patients at increased mortality risk, with SGRQ total score emerging as the strongest predictor
compared with other baseline covariates.
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Chronic obstructive pulmonary disease (COPD) is an increas-
ingly important cause of morbidity and mortality worldwide
and resulted inapproximately 3milliondeaths in 2002.1 Anum-
ber of risk factors predict an increased likelihood of COPD mor-
tality, although their impact may vary depending on disease
severity. Participation in a smoking cessation programme re-
duces the risk of mortality in patients with mild to moderate
airway obstruction2 whilst having a low body mass index
(BMI) contributes significantly to the risk of COPD death in pa-
tientswithmore severedisease.3 Other factorsassociatedwith
mortality from all causes in severe and very severe COPD in-
clude forced expiratory volume in 1 s (FEV1),
4 exercise capac-
ity,5 exacerbation frequency,6 the Medical Research Council
breathlessness score7 and health status measured using the
St George’s Respiratory Questionnaire (SGRQ).5,8 Several of
these variables have been combined to produce a grading sys-
tem, known as the BMI, airflow obstruction, dyspnoea and ex-
ercise capacity (BODE) index,9 which has stronger predictive
properties than the individual components alone.
Many of the treatments used in COPD affect the factors
known to predict mortality. Clinical trials lasting between 1
and 3 years have reported that combination therapy with
a long-acting b2-agonist (LABA) and an inhaled corticosteroid
(ICS) produce better lung function, fewer exacerbations and
better health status than either placebo or LABA alone.10e12
Several observational studies13,14 and a pooled analysis15
have suggested that ICS therapy may reduce mortality; how-
ever, the TOwards a Revolution in COPD Health (TORCH)
study showed no effect of the ICS fluticasone compared
with placebo, but there was a trend for the ICS/LABA combi-
nation used to reduce mortality.12 An apparent beneficial ef-
fect of ICS/LABA combination therapy on all-cause mortality
was also suggested in a recently published 2-year controlled
trial that included a treatment standardisation phase.16
This study was undertaken to examine the relationship
between the risk of death and baseline demographic and
clinical factors (specifically measures of health status and
lung function) as well as treatment allocation in a retro-
spective analysis of data from two clinical trial populations.
It also examines whether these factors can identify patients
at greatest risk of death and how this is affected by
therapy. Furthermore, this study provides an evaluation
of outcome measures that can be used to adequately power
prospective studies in order to investigate the effects of
ICS/LABA combinations and other therapy on mortality.
Methods
Patients
The investigation described is a pooled analysis of two
pivotal clinical studies, here called Study A10 and Study B,11evaluating the efficacy and safety of the combination of bu-
desonide and formoterol versus the respective components
and placebo in severe COPD over a 1-year period. Patients
were selected according to the following criteria: outpa-
tients aged 40 years; COPD symptoms for 2 years;
10 pack-years’ smoking history; FEV1/vital capacity
(VC) 70%; FEV1 50% of predicted normal (PN) measured
as pre-bronchodilator values (Global Initiative for COPD
[GOLD] stage III and IV);17 use of short-acting inhaled bron-
chodilators for reliever medication and 1 severe COPD ex-
acerbation within 2e12 months before the first clinic visit.
Study design and treatments
The studies were randomised, double-blind, placebo-con-
trolled, parallel group, multicentre investigations. Both
studies had a generally identical design for the 1-year
treatment period but different run-in periods. Patients in
Study A10 received oral prednisolone and inhaled formoterol
(Oxis Turbuhaler) in addition to terbutaline (Bricanyl
Turbuhaler) as needed in order to standardise health sta-
tus, while all maintenance medication was withdrawn
from patients in Study B,11 who only received terbutaline
as needed during run-in. Terbutaline as needed was allowed
as reliever medication in all treatment arms throughout the
studies. Primary endpoints in both studies included the rate
of exacerbations, time to first exacerbation and changes in
FEV1. Secondary endpoints, described in full elsewhere,
10,11
included health status measured using the disease-specific
SGRQ and the generic 36-item short-form health survey
(SF-36), breathlessness and other spirometry measurements
in addition to FEV1 (slow VC). Safety was evaluated by a stan-
dard question at each clinic visit, withdrawal due to disease,
patients’ adverse event reports and in-study mortality.
Assessments at baseline
Baseline covariates assessed for prediction of mortality risk
included pre- and post-bronchodilator FEV1, lung function
reversibility, FEV1/VC, age, gender, BMI, smoking status
and history, and ICS or LABA use before study, as assessed
at study entry. Other covariates collected at visits included
health status as measured by the SGRQ and the SF-36
questionnaire at randomisation, mean breathlessness score
during run-in and treatment allocation to budesonide-con-
taining treatment (budesonide/formoterol and budesonide)
versus non-budesonide treatment (formoterol and placebo)
or formoterol-containing treatment (budesonide/formo-
terol and formoterol) versus non-formoterol treatment (bu-
desonide and placebo).
The SGRQ and the SF-36 questionnaire were completed
at recruitment (visit 1; in Study B for training purposes only)
and at randomisation (visit 2) and subsequent clinic visits in
both Study A and Study B. SGRQ total scores and scores
Table 1 Demographic and baseline clinical characteristics
of the study populations at baseline and for in-study fatal
outcomes
Characteristic Patients at
baseline
In-study fatal
outcomes
No. of patients
(% men)
1834 (77) 56 (86)
Randomised to:
budesonide/non-
budesonide
917/917 22/34
Lung function
Mean FEV1, l 0.99 0.95
Mean FEV1, PN pre-
bronchodilator, %
36.1 35.7
Mean FEV1, PN post-
bronchodilator, %
41.8 40.7
Mean reversibility, PN, % 5.8 5.2
Mean FEV1/VC, % 43.0 44.4
Predictors of mortality in COPD 1617from the three domains of the SGRQ (activity, symptoms
and impact) were calculated. A higher score indicates
deteriorating health status while a change of 4 units indi-
cates the minimal clinically important difference relevant
to patients.8 The SF-36 score was calculated for each of
its two components: the mental component summary
(MCS) and physical component summary (PCS), where
a lower score indicates poor health status in that compo-
nent. For the reversibility test, FEV1 was measured before
and 15 min after two inhalations of terbutaline 0.5 mg
and the percentage increase from baseline in FEV1 was cal-
culated. Serious adverse events were recorded by the in-
vestigator after the study ended. Narratives on serious
adverse events and deaths, including the physician’s evalu-
ation of cause(s) of death, were obtained. Each case of
death was assigned post hoc to one of the following classes:
death due to an exacerbation of COPD; death due to an-
other respiratory cause; cardiac death; vascular death;
other cause (not respiratory, cardiac or vascular), or cause
of death unknown. No follow-up with regard to mortality
was conducted for patients who withdrew from the study
and thus full intention-to-treat analysis was not possible.Randomised patients
with pre-bronchodilator
FEV1 of:
30% PN, % 29 23
>30% PN, % 71 68
Randomised patients with
post-bronchodilator
FEV1 of:
50% PN, % 75 79
>50% PN, % 25 21
Mean age, years (range) 64 (40e92) 65 (45e92)
Median time since
diagnosis, years (range)
5 (0e55) 5 (1e30)
ICS use at entry, n (%) 706 (38) 19 (34)
LABA use at entry, n (%) 475 (26) 7 (13)
Smoking history
Current/past smoker, % 35/65 32/68
Mean no. of pack-years
(range)
41 (10e240) 39 (10e90)
Mean BMI, kg/m2 (range) 24.6
(13.0e47.6)
23.6
(14.7e41.2)
Breathlessness, run-in
mean score (0e4)
1.64 1.77
SGRQ, mean scorea
Total score 50.1 59.3
Symptom 59.4 64.2
Activity 63.0 71.0
Impact 42.4 53.9
SF-36, mean scorea
PCS 36.6 34.4
MCS 46.6 42.5
FEV1, forced expiratory volume in 1 s; PN, predicted normal;
VC, vital capacity; ICS, inhaled corticosteroid; LABA, long-
acting b2-agonist; BMI, body mass index; SGRQ, St George’s
Respiratory Questionnaire; SF-36, short-form (36-item) health
survey; PCS, physical component summary; MCS, mental com-
ponent summary.
a Score at randomisation.Analysis
A pooled analysis was performed using the baseline cova-
riates and the mortality data from the 1-year treatment
period of Study A10 and Study B.11 A recent pooled analysis
of seven large, well-controlled studies e the Inhaled
Steroids Effects Evaluation in COPD (ISEEC) study15 e
included only the budesonide and placebo arms of Studies
A and B, and so, in the current pooled analysis, a full anal-
ysis was performed of budesonide-containing arms versus
non-budesonide arms and formoterol-containing treatment
versus non-formoterol treatment. Descriptive statistics
were used to evaluate demographic and baseline character-
istics in both studies. The effect of treatment allocation on
survival times was compared with a log-rank test stratified
by study, and further descriptions were obtained by Cox re-
gression, with treatment as a factor and stratification by
study.
A Cox regression model stratified by study and region
(Europe or non-Europe) was used to assess the predictive
value of the baseline covariates. A univariate approach was
chosen as the starting point because of the limited number
of events, and covariates were added to the model one at
a time. The p-value of the regression coefficient was used
to discriminate between baseline variables, and the consis-
tency of this approach was checked with the Bayesian infor-
mation criterion.18,19 The most significant baseline variable
was added to the model and then the process was repeated
over the remaining baseline variables. Data on health status
from visit 2 (after run-in) were used in the main analysis.
However, an additional investigation using health status
data from visit 1 (before run-in treatment intensification)
in Study A was also conducted. In approximately 10% of fa-
tal outcomes there were missing data for baseline covari-
ates, and imputation for all missing covariates was
performed using an adaptation of the multiple imputations
model described by Schafer;20 p-values and confidence in-
tervals (CIs) were then adjusted accordingly. Penalised
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Figure 1 KaplaneMeier plots of the withdrawal rates in Study A and Study B. This figure shows the proportion of patients remain-
ing in the study over 1 year. In both studies the budesonide/formoterol-treated patients showed the lowest withdrawal rate and
placebo the highest. Patients treated with formoterol or budesonide alone in Study A showed a similar withdrawal pattern to
the placebo group, possibly an effect of the withdrawal of oral steroids and formoterol after treatment intensification during
run-in, while in Study B both the formoterol and budesonide groups showed a lower withdrawal rate than placebo. In Study A
the majority of patients who withdrew did so in the first 3e6 months; a pattern also observed in the budesonide and formoterol
arms in Study B. Study A: ***pZ 0.001 budesonide/formoterol versus placebo, pZ 0.037 budesonide/formoterol versus budeso-
nide, p < 0.001 budesonide/formoterol versus formoterol. Study B: ***pZ 0.001 budesonide/formoterol versus placebo,
**pZ 0.01 formoterol versus placebo, *p < 0.05 budesonide versus placebo.
1618 D.M.G. Halpin et al.spline modelling21 was used to describe the form of the re-
lationship between clinical covariates and mortality on the
logarithmic scale, i.e. to investigate possible deviations
from a pure linear relationship, the most known non-linear
relationship probably being the J- or U-shaped association
between BMI and risk of death.22 The possibility of time-
varying effects were also assessed using a proportional
hazards model.23 KaplaneMeier curves were used to illus-
trate the effect of treatment allocation on mortality.
Results
Baseline characteristics and patient population
The baseline demographic and clinical characteristics of
the pooled study population (nZ 1834) are presented in
Table 1. The 1-year studies were completed, according to
protocol, by 1166 patients, of whom 1083 were in-study
at day 360 and 840 were in-study at day 365. A total of
668 patients did not complete the studies (due to COPD
worsening, other adverse events or other reasons) and 56
patients died during the course of the studies. The placebo
group had the largest number of dropouts (Fig. 1), with the
budesonide/formoterol combination group showing the
lowest drop-out rate. In Study A the budesonide group
showed a lower withdrawal rate than placebo and the for-
moterol group had a similar rate of withdrawal to placebo
while in Study B the withdrawal rates in the formoterol
and budesonide groups were similar, showing a pattern
closer to the rate of withdrawal with budesonide/formo-
terol than to the higher rate with placebo (Fig. 1).
Mortality rates
There were fewer deaths among those receiving budeso-
nide-containing therapy (budesonide alone or budesonide/formoterol combination), with 22 of the total 56 deaths over
the 1-year treatment period in the pooled studies occurring
in this group and 34 occurring in the non-budesonide group
(pZ 0.036 by log-rank test). Cox regression analysis with
stratification by study only showed a hazard ratio (HR) of
0.564 in favour of the budesonide group (95% CI 0.327e
0.972; pZ 0.039; Fig. 2A). COPD was the leading cause of
mortality, with six deaths occurring in the budesonide group
versus 16 deaths in the non-budesonide group (Table 2i).
Deaths from other respiratory causes occurred in equal num-
bers in budesonide and non-budesonide treatment groups
(three patients in each group), and in similar numbers in for-
moterol and non-formoterol groups (two and four patients
respectively). The risk of cardiac death was similar between
groups (five patients in both budesonide and non-budesonide
treatment groups, six patients in the formoterol group and
four in the non-formoterol treatment group; Table 2i). The
distribution of deaths from any cause between formoterol-
containing and non-formoterol treatments was 31 and 25,
respectively (of which 12 versus 10 were COPD deaths,
respectively; Table 2ii) (HR 1.102 [95% CI 0.648e1.875];
pZ 0.720) (Fig. 2B).Baseline covariates as predictive
factors for mortality
Using Cox regression modelling, the SGRQ total score and
the SGRQ impact score were the most significant baseline
predictors of mortality (p < 0.0001) (Table 3). The SGRQ ac-
tivity score, SF-36 MCS, SF-36 PCS and SGRQ symptom score
were additional significant predictors of mortality (all
p < 0.05) while breathlessness, age, lung function mea-
sured as pre- and post-bronchodilator FEV1 (actual and per-
centage PN), reversibility, BMI and smoking history or status
were not predictive (Table 3). In a separate analysis on the
value of treatment allocation as a predictor of mortality,
A B
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Figure 2 KaplaneMeier curves for mortality. KaplaneMeier curves for mortality for budesonide versus reference (non-budeso-
nide) groups (A) and formoterol versus reference (non-formoterol) groups (B), including stratification by St George’s Respiratory
Questionnaire (SGRQ) total score (C,D). (A) Survival curves in the budesonide-treated patients (budesonide/formoterol and bude-
sonide) versus the reference group (formoterol and placebo), showing separation between the two groups in favour of budesonide-
treated patients. (C) Budesonide versus reference (non-budesonide) treatment groups separated by the median cut-off in SGRQ
total score of 50 points, demonstrating that the majority of deaths occurred among patients with an SGRQ total score >50 points
and who were not treated with budesonide-containing therapy. (B) Survival curves for the formoterol-treated population (budeso-
nide/formoterol and formoterol) versus the reference group (budesonide and placebo), with no difference in mortality rates indi-
cated. (D) This may indicate a minor separation between the formoterol and reference (non-formoterol) groups, in patients with
very poor health status (SGRQ total score >50 points).
Predictors of mortality in COPD 1619budesonide-containing treatment was found to decrease
the risk of death, with the p-value retaining significance af-
ter adjustment for SGRQ total score (HR 0.542 [95% CI
0.312e0.942]; pZ 0.03). On adjustment both for SGRQ to-
tal score and for allocation to budesonide treatment, all
other predictors of mortality became non-significant.
KaplaneMeier curves showed improved survival in patients
receiving budesonide-containing treatment, with promi-
nent separation between budesonide versus non-budesonide
treatments among those with higher SGRQ total scores
(Fig. 2C). Allocation to formoterol-containing treatment
showed a similar mortality distribution as non-formoterol
therapy in the whole population (Fig. 2B) with little separa-
tion between treatments at higher SGRQ scores (Fig. 2D).
After 1 year, a four-point higher SGRQ baseline score
was associated with a 15.7% increase (95% CI 8.8e23.2) in
the risk of all-cause mortality as calculated by standard
Cox regression. Using SGRQ data from visit 1 in Study A,
i.e. before treatment intensification, did not change the
power of SGRQ total score as a predictor of mortality. Aproportional hazards model with baseline SGRQ total score
as time-varying effect indicated that the mortality risk as-
sociated with SGRQ total score increased linearly over time
before reaching a plateau at around 6 months, signifying
that there is a maintained high mortality risk at high
SGRQ levels (Fig. 3).
Penalised spline modelling of baseline covariates indi-
cated a linear relationship between the disease-specific
health status assessment tool, SGRQ total and impact scores,
and the risk of mortality over the entire range of SGRQ scores
(Fig. 4A,B). This observation was supported by spline analysis
of the general health status assessment tool SF-36 which
showed a linear relationship over the major part of the inter-
val (not shown). Age appeared to be associated with a bi-
modal distribution of risk (Fig. 4C), with a plateau between
60 and 80 years, while BMI had a U-shaped risk distribution
with the lowest risk at a BMI of approximately 30 (Fig. 4D). Al-
though observations were outside the significance level, the
spline analysis of lung function variables indicated that there
was a linear association between declining lung function and
Table 2 Causes of mortality in the pooled studies for (i) budesonide-containing versus non-budesonide therapy and (ii) for-
moterol-containing versus non-formoterol therapy
Cause of mortality (i) (ii)
Budesonide-containing
therapya
Non-budesonide
therapyb
Formoterol-containing
therapyc
Non-formoterol
therapyd
COPD (n) 6 16 12 10
Other respiratory (n) 3 3 2 4
Cardiac (n) 5 5 6 4
Other vascular (n) 0 5 4 1
Othere (n) 6 4 6 4
Unknown (n) 2 1 1 2
Total 22 34 31 25
This table shows two different analyses (budesonide-containing versus non-budesonide therapy and formoterol-containing versus non-
formoterol therapy) conducted on the same patients from Study A and Study B in both cases.
a Budesonide/formoterol or budesonide.
b Formoterol or placebo.
c Budesonide/formoterol or formoterol.
d Budesonide or placebo.
e Other includes cancer, diarrhoea, gastric ulcer, pulmonary embolism.
1620 D.M.G. Halpin et al.mortality risk for FEV1 above 1.2 l (pre-bronchodilator) while
below this level there was no further discriminative predic-
tive value (Fig. 4E). Spline analysis of FEV1 PN values showed
a different pattern with a distinct plateau in the range be-
tween approximately 30 and 60% in post-bronchodilator
FEV1 and an apparent increased risk below 30% (Fig. 4F).
The pre-bronchodilator FEV1 PN showed a similar curveTable 3 Predictive value of baseline covariates for mortalitya
Added variable Hazard ratio
SGRQ total score 1.037
SGRQ impact score 1.029
SGRQ activity score 1.030
SF-36 MCS 0.962
SF-36 PCS 0.960
SGRQ symptom score 1.017
Breathlessness 1.242
FEV1 (post-bronchodilator, post-run-in) 0.578
BMI <21 kg/m2 1.508
BMI (kg/m2) 0.962
Reversibility difference (l) 0.471
Pack-years of cigarette smoking 0.994
Age (years) 1.015
FEV1 (post-bronchodilator) >30% of PN 0.746
Reversibility (% PN) 0.983
FEV1 (% VC) 1.010
Smoking status (past/current) 1.193
FEV1 (post-bronchodilator) >50% of PN 0.879
FEV1 (pre-bronchodilator) 0.803
FEV1 (% PN post-bronchodilator) 0.997
FEV1 (% PN pre-bronchodilator) 1.003
FEV1 (% PN pre-bronchodilator) >30% of PN 0.972
SGRQ, St George’s Respiratory Questionnaire; SF-36, short-form (36-ite
component summary; FEV1, forced expiratory volume in 1 s; BMI, bod
a Cox regression analysis stratified by study and region only. One va
b p-value for the regression coefficient with only that variable in the
the analysis was adjusted for SGRQ total score.(Fig. 4G), indicating that bronchodilator response may play
a role. The spline curve for reversibility (Fig. 4H) supports
this observation, showing a linear relationship between mor-
tality risk and decreasing bronchodilator response. Gender
and ICS and/or LABA use at study entry were analysed sepa-
rately as there were zero cases in some strata, but results
indicated that these factors were of less predictive value.95% confidence interval p-value (exploratory)b
1.021e1.054 <0.0001
1.016e1.043 <0.0001
1.014e1.046 0.0002
0.937e0.987 0.0032
0.928e0.993 0.0179
1.002e1.031 0.0220
0.965e1.599 0.0925
0.290e1.153 0.1196
0.849e2.676 0.1607
0.905e1.023 0.2208
0.119e1.867 0.2841
0.982e1.006 0.3286
0.985e1.047 0.3292
0.391e1.426 0.3754
0.944e1.022 0.3866
0.987e1.032 0.4008
0.669e2.125 0.5501
0.462e1.672 0.6940
0.340e1.894 0.6158
0.975e1.019 0.7840
0.976e1.031 0.8177
0.545e1.732 0.9221
m) health survey; MCS, mental component summary; PCS, physical
y mass index; PN, predicted normal; VC, vital capacity.
riable at a time was added to the model.
model. All other baseline predictors became non-significant when
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Figure 3 Proportional hazards model of time-varying effects
of SGRQ total score on mortality risk. The black curve repre-
sents the cumulative regression curve; the grey curves repre-
sent the associated 95% confidence intervals (CIs). The
increase in mortality risk over time is more marked during
the first 6 months of the study, after which the risk levels out
slightly although continues to increase over time. Translated
into the risk associated with a four-point higher St George’s Re-
spiratory Questionnaire (SGRQ) baseline score, there was
a 15.7% increase (95% CI 8.8e23.2, standard Cox regression)
in the risk of all-cause mortality after 1 year.
Predictors of mortality in COPD 1621Discussion
This pooled analysis reports that poor baseline health
status, as indicated by SGRQ and SF-36 scores, is a signifi-
cant predictor of mortality in patients with severe COPD,
with SGRQ total score emerging as the strongest predictor
compared with other baseline covariates.
Improvement of health status in COPD patients is one of
the key treatment goals according to GOLD management
guidelines.17 However, the difficulties associated with quan-
tifying a clinically important improvement in day-to-day
practice are well-recognised. This study used baseline
values as predictors of mortality over a 1-year period and re-
ports that mortality was higher in patients with high SGRQ
scores at randomisation. The linear relationship observed
in the spline analysis shows that there is in fact an exponen-
tial relationship between health status and risk of death as
the data were logarithmically transformed. The SGRQ mea-
surement is known to be a valuable means of consistently
assessing deteriorating health status in patients with moder-
ate to very severe COPD24 and, while several studies have
reported the disease-specific SGRQ25 as being predictive of
mortality in COPD,5,8,26,27 this is one of the few studies to re-
port that the generic SF-36 questionnaire can also be useful
for identifying vulnerable patients.25
Conventionally, COPD is defined as mild, moderate
or severe, based on measures of lung function.17 Although
a relationship has been reported between low FEV1 andmortality,4,26,28 spline analysis performed in the present
study suggests that FEV1 was only discriminative in predic-
tion of mortality risk when FEV1 had not fallen below 1.2 l
(pre-bronchodilator) (Fig. 4). Bronchodilator response, on
the other hand, showed a linear correlation with mortality
risk, with a lower risk in the more responsive patients
(Fig. 4). Our population had a mean FEV1 of 0.99 l, with
an inclusion criterion of pre-bronchodilator FEV1 50%,
suggesting that FEV1 is indeed a predictor of mortality in
patients with moderate, but not severe, COPD but may also
be linked to the degree of reversibility, which in this study
had a mean value of 5.8%. These observations are descrip-
tive in nature and warrant further investigation in larger
studies. Increasing age is known to be associated with mor-
tality risk,25,26 and spline analysis showed a linear relation-
ship from 40 to 60 years but a constant risk profile of
mortality from 60 to 80 years in the study. BMI had a U-
shaped distribution of risk, which has been observed in
other studies3,22 and is consistent with reports that a lower
BMI is linked to increased mortality risk.25,28,29 SGRQ total
score was the most informative baseline variable in the
spline analysis, demonstrating a linearly increasing mortal-
ity risk from 0 to 100 points. This baseline variable was also
a significant predictor of mortality while the other baseline
variables, described above, remain exploratory. The SF-36
questionnaire also showed a linearly distributed risk predic-
tion over the major part of the interval, in both the PCS and
the MCS, which levelled out in very severe COPD, but sup-
port the use of health status measurement in identifying
patients at risk. Although lung function is routinely mea-
sured in clinical practice, and bronchodilator response
may be of some guidance, these findings support existing
evidence that health status is a better predictor of admis-
sion to hospital and death within 12 months than FEV1
30
and suggest that health status assessment should become
standard in COPD management.
A recent meta-analysis conducted by Salpeter and
colleagues31 suggested that LABA may compromise the
long-term safety of COPD patients. This is, however, not
consistent with the findings of the current study, nor with
the results from a large, 3-year controlled study in COPD
with all-cause mortality as the primary outcome.12 Indeed,
the LABA treatment group in the TORCH study12 had the
lowest incidence of cardiovascular deaths among all treat-
ment arms including placebo.
The benefit of budesonide in reducing 1-year all-cause
mortality in this study is in agreement with previous
observational studies suggesting a benefit of ICS therapy
in reducing COPD mortality13,14,32 and a pooled analysis of
seven large controlled trials.15 The ISEEC study included
data on budesonide and placebo arms from the material
presented in this analysis and reported approximately
a 25% reduction in mortality with ICS compared with pla-
cebo.15 The present results are also in agreement with
data from the 3-year European Respiratory Society’s study
on Chronic Obstructive Pulmonary Disease (EUROSCOP).33
The EUROSCOP data were not included in the current study
because of differences in baseline data, including a lack of
health status measurements, although all-cause mortality
data are supportive when included in the Cox regression
analysis. Furthermore, the TORCH study12 found no mortal-
ity reduction over 3 years with fluticasone over placebo,12
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Figure 4 Penalised splines for covariates at baseline as predictors of mortality, evaluated on a logarithmic scale. Each panel shows
the shape of the association between the respective baseline covariate and risk of mortality over 1 year. The disease-specific health
status instrument, St George’s Respiratory Questionnaire (SGRQ impact score, A), shows a linear association with deteriorating health
status throughout the full interval, thus showing full discriminative predictive value throughout the range. The SGRQ total score (B)
also shows a linear association throughout the full interval. The spline of age distribution indicates an apparently increasing risk of
death in the interval between 40 and 60 years, but a constant association in the interval 60e80 years (C). A U-shaped association can
be observed between body mass index (BMI) and mortality (D), which confirms the findings of previous studies.22 (E) Linear association
between lung function and mortality in moderate disease, but no discriminative association is observed when lung function has fallen
below approximately 1.2 l (pre-bronchodilator value). (F) Mortality risk profile of post-bronchodilator predicted normal (PN) forced
expiratory volume in 1 s (FEV1), with an increasing risk below 30% while in the interval 30e60% there seems to be little predictive
value. (G) Pre-bronchodilator FEV1 (% of PN). (H) Apparent predictive correlation between poor lung function reversibility and
increasing mortality risk.
1622 D.M.G. Halpin et al.although there was a reduction in mortality risk with ICS/
LABA combination therapy. In this study, mortality from
ICS therapy alone was a secondary endpoint but the com-
pleteness of the follow-up to death strengthens its conclu-
sions. Whether similar data to those reported here would
be observed in patients from the TORCH study with similar
impairments in health status remains to be determined. An-
other 2-year study of an ICS/LABA combination therapy in
severe COPD patients reported a lower mortality ratewith combination therapy compared with tiotropium. How-
ever, this study did not examine the effects of ICS alone,
mortality was a tertiary outcome and the vital status of pa-
tients who did not complete the study was not deter-
mined.16 Further investigation into the potential mortality
benefit of ICS or ICS/LABA combinations is required.34
The current pooled analysis has several limitations.
Studies A and B were not designed to investigate mortality
and patients with co-morbidities or recent exacerbations
Predictors of mortality in COPD 1623(within 1 month prior to study start) were excluded. There
was also no post-withdrawal follow-up, so only data on
in-study mortality are provided. It has recently been re-
ported that differential discontinuation in randomised
trials is related to disease severity or progression and can
have profound effects on the interpretation of mortality
data in intention-to-treat analyses unless the vital status
of all trial participants is known at the end of the trial
period.35
Additionally, since mortality was a secondary outcome
measure, data on the cause of death were not listed
according to a pre-defined protocol, and each case may
have several causes listed. This retrospective study is
further limited by the difference in the run-in phases in
Study A and Study B.10,11 The drop-out rate due to disease
deterioration during the run-in phase was lower in Study A
(31/1141 enrolled) than in Study B (75/980 enrolled) be-
cause of treatment intensification during run-in. Further-
more, 48 versus 26% of patients in Study A and Study B,
respectively, were treated with ICS before randomisation.
Thus, it is possible that more steroid-dependent patients
were randomised in Study A due to the treatment intensifi-
cation during run-in, while Study B may have shown
a healthy survivor bias since maintenance medication, in-
cluding ICS, was withdrawn during run-in, resulting in
a larger drop-out rate during this phase.10,11 These limita-
tions reflect the difficulties associated with retrospective
determination of mortality risk.
Health status, as measured by the SGRQ total score, is an
important baseline variable for predicting in-study mortal-
ity. This knowledge should allow future studies using COPD
mortality in clinical trials as an outcome to identify a high-
risk population in whom the effect of treatment can be best
studied. Although currently designed for use in clinical
trials, health status assessment tools such as the SGRQ may
provide important information on COPD patients at in-
creased risk of death in daily clinical practice. The de-
velopment of a more readily applicable tool would greatly
help the application of this approach.
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